Targeting CSF1/CSF1R signaling in protumoral TAMs represents an attractive strategy for eliminating CSF1R-dependent or reprogramming M2-like TAMs in HCC (Pyonteck et al., 2013; Cannarile et al., 2017). This evidence concerns the gene CSF1 and hepatocellular carcinoma.